Key Points
- Director David Mahoney sold 103,606 Corcept Therapeutics shares at an average price of $118.25, generating $12.25 million. His remaining stake fell 8.37% to 1.13 million shares.
- Corcept reported stronger-than-expected quarterly results, with earnings of $0.36 per share versus a $0.02 estimate and revenue of $256.15 million, up 31.7% year over year.
- Analysts remain broadly positive: the stock has a “Moderate Buy” consensus rating and a $138.17 average price target, while recent targets range from $150 to $165.
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) Director David Mahoney sold 103,606 shares of the firm's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $118.25, for a total value of $12,251,409.50. Following the transaction, the director directly owned 1,133,539 shares in the company, valued at approximately $134,040,986.75. This represents a 8.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Corcept Therapeutics Stock Up 1.7%
Shares of CORT stock opened at $121.05 on Friday. The stock has a market capitalization of $13.09 billion, a PE ratio of 288.22 and a beta of 0.45. Corcept Therapeutics Incorporated has a 52-week low of $28.66 and a 52-week high of $122.21. The stock's 50-day moving average price is $96.60 and its 200 day moving average price is $64.19.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The firm had revenue of $256.15 million during the quarter, compared to the consensus estimate of $221.15 million. During the same period in the prior year, the business earned $0.29 EPS. The firm's revenue was up 31.7% compared to the same quarter last year. Analysts expect that Corcept Therapeutics Incorporated will post 1.61 earnings per share for the current fiscal year.
Analysts Set New Price Targets
CORT has been the subject of several recent research reports. Wall Street Zen raised Corcept Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 1st. Truist Financial began coverage on shares of Corcept Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $164.00 price objective on the stock. Piper Sandler reissued an "overweight" rating and issued a $165.00 price objective (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday, July 30th. HC Wainwright upped their price objective on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Finally, Canaccord Genuity Group raised their target price on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $138.17.
Check Out Our Latest Report on Corcept Therapeutics
Hedge Funds Weigh In On Corcept Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in CORT. Advisory Services Network LLC purchased a new position in shares of Corcept Therapeutics during the 3rd quarter worth approximately $25,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Corcept Therapeutics in the second quarter valued at approximately $27,000. Larson Financial Group LLC boosted its stake in shares of Corcept Therapeutics by 2,326.3% in the third quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company's stock valued at $38,000 after buying an additional 442 shares in the last quarter. Gould Capital LLC grew its holdings in Corcept Therapeutics by 50.0% during the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company's stock worth $50,000 after acquiring an additional 200 shares during the period. Finally, Torren Management LLC acquired a new position in Corcept Therapeutics during the fourth quarter worth $25,000. Institutional investors and hedge funds own 93.61% of the company's stock.
About Corcept Therapeutics
(
Get Free Report)
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
